Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

Next generation sequencing for personalized therapy: About a class III BRAF N581K mutation associated to NRAS Q61L mutation in malignant melanoma: Case report

In metastatic stage, therapeutic approach for malignant melanoma is particularly based on performance status, metastatic sites, and BRAF V600 status (BRAF V600E/V600K or V600R (class I BRAF mutations). In most cases, BRAF mutations and NRAS mutations are mutually exclusive to each other. However, so...

Full description

Bibliographic Details
Main Authors: Manuel Croix, Guénaëlle Levallet, Nicolas Richard, Claire Bracquemart, Taha Tagmouti, Anne Dompmartin, Diane Kottler, Jean Matthieu L'Orphelin
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Heliyon
Subjects:
Melanoma
BRAF
NRAS
Non V600 mutant
Treatment NGS
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023056281

Similar Items

Similar Items